🇺🇸 phosphomycin in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 11
Most-reported reactions
- Condition Aggravated — 2 reports (18.18%)
- Anorexia — 1 report (9.09%)
- Arthritis — 1 report (9.09%)
- Atrioventricular Block Complete — 1 report (9.09%)
- Blood Lactic Acid Increased — 1 report (9.09%)
- Blood Potassium Decreased — 1 report (9.09%)
- Bradycardia — 1 report (9.09%)
- Brain Herniation — 1 report (9.09%)
- Brain Oedema — 1 report (9.09%)
- Hypocapnia — 1 report (9.09%)
Other Other approved in United States
Frequently asked questions
Is phosphomycin approved in United States?
phosphomycin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for phosphomycin in United States?
Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.